Ancona International Airport Announces Management Transition
ANCONA, Italy--(BUSINESS WIRE)--Ancona International Airport ('AIA'), a Njord Partners portfolio company, announces that its CEO, Alex D'Orsogna, will be taking up the role of General Director of ENAC Italy, the national civil aviation authority. He was appointed to the post on 16 June 2025 by the Italian Prime Minister.
Hamish de Run, the current President and Chair of AIA since 2019, will assume the role of Interim CEO while the search for a permanent successor is conducted.
Since joining AIA in 2022, Alex has been instrumental in repositioning the airport as a vital logistics hub both nationally and internationally. Under his leadership, AIA has achieved record growth in both freight and passenger operations, launching several infrastructure and intermodal initiatives that have established Ancona as a strategic transport center.
Alex's departure coincides with an exciting phase of momentum for AIA, as the airport continues its ambitious strategic transformation. The flagship Verticall project remains on schedule, with the first phase set for completion in 2025 and full construction anticipated to commence in 2026. Additionally, in Q325, Amazon will inaugurate a new operations facility just 6 km from the airport, positioning AIA to emerge as one of Italy's top five cargo hubs. Further, AIA continues to focus on the launch of the spaceport project, establishing Italy's autonomous industrial access to space, as well as currently instituting itself as an important MRO location.
AIA's unique intermodal triangle, linking airport, port, and rail within a 10 km radius, has garnered recognition from both the Italian government and the European Commission as a national model for integrated infrastructure and logistics. Ongoing investment to connect the hub to Italy's high-speed rail network will further enhance its strategic importance.
Hamish de Run, Chair and Interim CEO, commented: 'We are immensely grateful to Alex for his exceptional leadership, commitment, and vision. His transformative contributions have significantly shaped Ancona's growth and enhanced its reputation, leaving us well-positioned for continued success. I am excited to work closely with the management team to build upon this momentum as we embark on our next exciting chapter.'
About Ancona International Airport
Ancona International Airport, known as Marche Airport, is the primary airport serving the Marche region of Italy. As a multi-dimensional airport, it offers both domestic and international flights as well as private jets, connecting the region with major European destinations. Renowned for its operational efficiency and traveller convenience, Ancona International occupies a central position within the regional transportation network, supporting both commercial and leisure travel. Beyond its passenger services, the airport serves as a vital hub for cargo operations, facilitating freight and logistics, while also building a potential pivotal role in aircraft maintenance, recovery and conversion. Additionally, the Airport is building a path in serving as a focal point for various aerospace research and development initiatives, further solidifying its significance in advancing new aviation technologies and innovation. To find out more visit: https://www.ancona-airport.com/en/.
About Njord Partners
Njord Partners is a special situations investment manager and provider of long-term flexible capital solutions. Established in 2013, Njord Partners manages capital in excess of €1 billion. Investing in European middle-market companies facing complex situations, its mission is to deliver superior risk-weighted returns to investors while preserving capital. As a capital partner, Njord Partners offers flexible debt and equity solutions, actively facilitating strategic and operational enhancements within its portfolio companies to drive value.
To find out more visit: https://njordpartners.com/.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
18 minutes ago
- Yahoo
Billionaire Brighton owner Tony Bloom buys stake in Scottish soccer club Hearts
Brighton and Hove Albion owner Anthony Bloom and his wife Linda in the stands just before kick off of the the English FA Cup semifinal between Manchester United and Brighton and Hove Albion at Wembley Stadium in London, Sunday, April 23, 2023 (AP Photo/Alastair Grant) EDINBURGH, Scotland (AP) — Brighton soccer club's billionaire owner Tony Bloom invested in Heart of Midlothian of the Scottish Premiership on Wednesday, aiming to revive another unheralded team. The former professional poker player is seen as one of the smartest investors in European soccer helping lift his hometown club Brighton and current Belgian champion Union Saint-Gilloise to unexpected success with data-driven research and management. Advertisement Hearts said Bloom paid 9.86 million pounds ($13.4 million) for 'a 29% stake in the club in non-voting shares.' The size of Bloom's minority stake should be within the UEFA-set threshold to comply with rules designed to protect the integrity of European competitions when clubs in shared ownership both qualify. UEFA required Bloom to reduce his stake and decision-making influence at Union in 2023 when the club from Brussels joined Brighton in qualifying for the second-tier Europa League. Union won its first Belgian league title in 90 years this season and will make its debut in the Champions League main phase. Brighton missed qualifying for UEFA competitions by one place finishing eighth in the Premier League. Advertisement Hearts played in the third-tier Conference League last season but did not qualify for any European competition next season after placing seventh in the Scottish league. The Edinburgh club won the last of its four titles in 1960 in a league now monopolized by Glasgow rivals Celtic and Rangers. They have combined to win the last 40 titles. 'I am absolutely thrilled to be investing in Hearts,' Bloom said in a club statement. 'I firmly believe in the club's ability to disrupt the pattern of domination of Scottish football which has been in place for far too long.' Hearts has been runner-up five times since 1960, most famously in 1986 after leading the standings for months. Hearts lost on the last day by conceding two late goals at Dundee and was overtaken by Celtic. ___ AP soccer:
Business Wire
22 minutes ago
- Business Wire
PennyMac Mortgage Investment Trust Declares Second Quarter 2025 Dividend for Its Common Shares
WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)--PennyMac Mortgage Investment Trust (NYSE: PMT) announced today that its Board of Trustees declared a cash dividend of $0.40 per common share of beneficial interest for the second quarter of 2025. This dividend will be paid on July 25, 2025, to common shareholders of record as of July 11, 2025. About PennyMac Mortgage Investment Trust PennyMac Mortgage Investment Trust is a mortgage real estate investment trust (REIT) that invests primarily in residential mortgage loans and mortgage-related assets. PMT is externally managed by PNMAC Capital Management, LLC, a wholly-owned subsidiary of PennyMac Financial Services, Inc. (NYSE: PFSI). Additional information about PennyMac Mortgage Investment Trust is available at Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, regarding management's beliefs, estimates, projections and assumptions with respect to, among other things, the Company's financial results, future operations, business plans and investment strategies, as well as industry and market conditions, all of which are subject to change. Words like 'believe,' 'expect,' 'anticipate,' 'promise,' 'plan,' and other expressions or words of similar meanings, as well as future or conditional verbs such as 'will,' 'would,' 'should,' 'could,' or 'may' are generally intended to identify forward-looking statements. Actual results and operations for any future period may vary materially from those projected herein and from past results discussed herein. Factors which could cause actual results to differ materially from historical results or those anticipated include, but are not limited to: changes in interest rates; the Company's ability to comply with various federal, state and local laws and regulations that govern its business; volatility in the Company's industry, the debt or equity markets, the general economy or the real estate finance and real estate markets; events or circumstances which undermine confidence in the financial and housing markets or otherwise have a broad impact on financial and housing markets; changes in real estate values, housing prices and housing sales; changes in macroeconomic, consumer and real estate market conditions; the degree and nature of the Company's competition; the availability of, and level of competition for, attractive risk-adjusted investment opportunities in mortgage loans and mortgage-related assets that satisfy the Company's investment objectives; the inherent difficulty in winning bids to acquire mortgage loans, and the Company's success in doing so; the concentration of credit risks to which the Company is exposed; the Company's dependence on and potential conflicts with its manager, servicer and their affiliates; the Company's ability to mitigate cybersecurity risks, cybersecurity incidents and technology disruptions; the development of artificial intelligence; the availability, terms and deployment of short term and long term capital; the adequacy of the Company's cash reserves and working capital; the Company's ability to maintain the desired relationship between its financing and the interest rates and maturities of its assets; the timing and amount of cash flows, if any, from the Company's investments; the Company's substantial amount of indebtedness; the performance, financial condition and liquidity of borrowers; the Company's exposure to risks of loss and disruptions in operations resulting from severe weather events, man-made or other natural conditions, including climate change and pandemics; the ability of the Company's servicer, which also provides the Company with fulfillment services, to approve and monitor correspondent sellers and underwrite loans to investor standards; incomplete or inaccurate information or documentation provided by customers or counterparties, or adverse changes in the financial condition of the Company's customers and counterparties; the Company's indemnification and repurchase obligations in connection with mortgage loans it purchases, sells or securitizes; the quality and enforceability of the collateral documentation evidencing the Company's ownership and rights in the assets in which it invests; increased rates of delinquency, defaults and forbearances and/or decreased recovery rates on the Company's investments; the performance of mortgage loans underlying mortgage-backed securities in which the Company retains credit risk; the Company's ability to foreclose on its investments in a timely manner or at all; increased prepayments of the mortgages and other loans underlying the Company's mortgage-backed securities or relating to the Company's mortgage servicing rights and other investments; risks associated with the discontinuation of LIBOR; the degree to which the Company's hedging strategies may or may not protect it from interest rate volatility; the effect of the accuracy of or changes in the estimates the Company makes about uncertainties, contingencies and asset and liability valuations when measuring and reporting upon the Company's financial condition and results of operations; the Company's ability to maintain appropriate internal control over financial reporting; the Company's ability to detect misconduct and fraud; developments in the secondary markets for the Company's mortgage loan products; legislative and regulatory changes that impact the mortgage loan industry or housing market; regulatory or other changes that impact government agencies or government-sponsored entities, or such changes that increase the cost of doing business with such agencies or entities; federal and state mortgage regulations and enforcement; changes in government support of homeownership; changes in government or government-sponsored home affordability programs; changes in the Company's investment objectives or investment or operational strategies, including any new lines of business or new products and services that may subject it to additional risks; limitations imposed on the Company's business and its ability to satisfy complex rules for it to qualify as a REIT for U.S. federal income tax purposes and qualify for an exclusion from the Investment Company Act of 1940 and the ability of the Company's subsidiaries to qualify as REITs for U.S. federal income tax purposes; changes in governmental regulations, accounting treatment, tax rates and similar matters; the Company's ability to make distributions to its shareholders in the future; the Company's failure to deal appropriately with issues that may give rise to reputational risk; and the Company's organizational structure and certain requirements in its charter documents. You should not place undue reliance on any forward-looking statement and should consider all of the uncertainties and risks described above, as well as those more fully discussed in reports and other documents filed by the Company with the Securities and Exchange Commission from time to time. The Company undertakes no obligation to publicly update or revise any forward-looking statements or any other information contained herein, and the statements made in this press release are current as of the date of this release only.
Business Wire
22 minutes ago
- Business Wire
Acadia Pharmaceuticals Hosts Inaugural R&D Day Showcasing Pipeline and Long-Term Value Drivers
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) will host its inaugural 2025 R&D Day today to highlight its key pipeline programs and their potential to drive long-term growth. Across nine disclosed programs, the Company anticipates initiating seven Phase 2 or Phase 3 studies during 2025-2026. Acadia further anticipates reporting five Phase 2 or Phase 3 study readouts during 2025-2027—underscoring the breadth of its pipeline and the momentum behind its R&D strategy. Q3 2025 - Phase 2 study initiation for ACP-204 in Lewy Body Dementia Psychosis (LBDP) Q3 2025 - Phase 3 study initiation in Japan for trofinetide in Rett syndrome Early Q4 2025 - Topline results for the COMPASS PWS Phase 3 study of ACP-101 in Prader-Willi syndrome (PWS) following the recent completion of enrollment Q4 2025 - Phase 2 study initiation for ACP-211 in major depressive disorder (MDD) Q4 2025 - First in human study of ACP-271 in healthy volunteers Q1 2026 - Potential approval from European Medicines Agency for trofinetide Mid-2026 - Topline results from ACP-204 Phase 2 study in Alzheimer's disease psychosis (ADP) 2026 - Phase 2 study initiation for ACP-711 in Essential Tremor (ET) 'Acadia is building from a position of strength, with two commercial franchises on track to deliver over $1 billion in net sales this year,' said Catherine Owen Adams, Chief Executive Officer. 'As we advance our pipeline, the five molecules we showcase today represent a multibillion-dollar incremental revenue opportunity. They also underscore our unwavering commitment to bold science and our focus on delivering transformative therapies for patients with serious and underserved neurological and rare diseases. We believe the opportunity ahead is extraordinary—and we are confident in our ability to execute with discipline and purpose as we work to build a biotech powerhouse.' 'At Acadia, we're building a strong, sustainable pipeline focused on progressing the most promising science with the goal of meaningfully improving patient care,' said Elizabeth H.Z. Thompson, Ph.D., Executive Vice President, Head of R&D. 'Our pipeline is moving forward with real momentum. Between now and the end of 2026, we plan to initiate seven Phase 2 or 3 studies, with five key readouts anticipated by the end of 2027. We remain deeply committed to advancing care in neurological and rare diseases, leveraging our development expertise and commercial strength to bring meaningful innovation to patients.' The Company will be discussing the following pipeline programs today: ACP-101 (intranasal carbetocin) A long-acting analogue of human oxytocin for the potential treatment of PWS ACP-204 A new, highly selective, potent inverse agonist of 5-HT2A that builds upon lessons learned from pimavanserin for the potential treatment of ADP and LBDP ACP-211 An orally administered, selectively deuterated form of R-Norketamine for the potential treatment of MDD ACP-711 A selective GABA A -α3 modulator targeting the potential treatment of ET ACP-271 A GPR88 agonist for the potential treatment of Tardive Dyskinesia and Huntington's Disease To register for the live webcast, please click here. A replay of Acadia's R&D Day will be available on the company's website, under the investors section for approximately 3 months following the event. About Acadia Pharmaceuticals Acadia is advancing breakthroughs in neurological and rare diseases to elevate life. Since our founding we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only FDA-approved drug to treat hallucinations and delusions associated with Parkinson's disease psychosis and the first and only approved drug in the United States and Canada for the treatment of Rett syndrome. Our clinical-stage development efforts are focused on Prader-Willi syndrome, Alzheimer's disease psychosis and multiple other programs targeting neuroscience and neuro-rare diseases. For more information, visit us at and follow us on LinkedIn and X. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements other than statements of historical fact and can be identified by terms such as 'may,' 'will,' 'should,' 'could,' 'would,' 'expects,' 'plans,' 'anticipates,' 'believes,' 'estimates,' 'projects,' 'predicts,' 'potential,' 'continue,' 'opportunity,' 'goal' and similar expressions (including the negative thereof) intended to identify forward-looking statements. Forward-looking statements contained in this press release, include, but are not limited to, statements about: (i) our business strategy, objectives and opportunities, including the timing for and clinical and market potential of our pipeline assets, and potential for enhanced shareholder value; (ii) plans for, including timing, development and progress of commercialization or regulatory timelines for our products, including NUPLAZID and DAYBUE, and our product candidates; (iii) benefits to be derived from and efficacy of our products, including the potential advantages of our products and product candidates; (iv) the timing and conduct of and topline results for our clinical trials, including the timing of topline results from our clinical trial in Prader-Willi syndrome, the continuing enrollment in our clinical trials in Alzheimer's disease psychosis, the initiation of our clinical trial in Lewy Body Dementia Psychosis, and the timing and content of our presentations or announcements regarding our clinical trials; (v) our estimates regarding our future financial performance, profitability, capital requirements or expenses, including estimates of potential commercial product and pipeline peak sales and potential net sales of our commercial franchises in 2025, and (vi) our ability to successfully complete additional business development transactions. Forward-looking statements are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause our actual results, performance or achievements to differ materially and adversely from those anticipated or implied by our forward-looking statements. Such risks, uncertainties and other factors include, but are not limited to: our dependency on the continued successful commercialization of our products and our ability to maintain or increase sales of our products; our plans to commercialize DAYBUE globally and trofinetide in the EU; the costs of our commercialization plans and development programs, and the financial impact or revenues from any commercialization we undertake; our ability to obtain necessary regulatory approvals for our product candidates and, if and when approved, market acceptance of our products; the risks inherent with product candidate development, including risks of unsuccessful clinical trial enrollment and negative or inconsistent results; our dependence on third-party collaborators, clinical research organizations, manufacturers, suppliers and distributors; the impact of competitive products and therapies; our ability to generate or obtain the necessary capital to fund our operations; our ability to grow, equip and train our specialized sales forces; our ability to manage the growth and complexity of our organization; our ability to maintain, protect and enhance our intellectual property; and our ability to continue to stay in compliance with applicable laws and regulations. Given the risks and uncertainties, you should not place undue reliance on these forward-looking statements. For a discussion of these and other risks, uncertainties and other factors that may cause our actual results, performance or achievements to differ, please refer to our annual report on Form 10-K for the year ended December 31, 2024 as well as our subsequent filings with the Securities and Exchange Commission from time to time, including our quarterly report on Form 10-Q for the quarter ended March 31, 2025. The forward-looking statements contained herein are made as of the date hereof, and we undertake no obligation to update them after this date, except as required by law.
